Monotherapy with Darunavir is Where the "MONET" is

Monotherapy with Darunavir is Where the "MONET" is

AIDS is a global pandemic whose cure has eluded scientists and doctors for more than 2 decades. Acquired immunodeficiency syndrome (AIDS) is caused by the Human Immunodeficiency Virus (HIV) which progressively undermines the strength of the immune system until such a time that the body becomes incapable of fighting off infections and vulnerable to opportunistic infections and tumors.

As of 2009, the World Health Organization estimates that there are 33.4 million people living with AIDS, with 2.7 million new HIV infections and another 2 million deaths reported each year. Since the first infection was reported in June 1981, drug companies worldwide have been coming up with new therapies and drugs to combat the rapidly growing pandemic. However, a complete viral cure remains elusive even now, with the best standard treatment at the moment being called triple drug arm antiretroviral therapy (ART). Highly active antiretroviral therapy (HAART) has proven to be very successful since its introduction in 1996. A typical HAART therapy consists of a protease inhibitor and two nucleoside analogue reverse transcriptase inhibitors (NARTIs). NARTIs such as Zidovudine CAS# 30516-87-1, Didanosine CAS# 69655-05-6 and Emtricitabine CAS# 143491-57-0 slow down the disease progression by interfering with the DNA synthesis. Protease inhibitors, on the other hand, such as Ritonavir CAS# 155213-67-5 prevent the replication of the HIV virus by inhibition of the protease enzymes.

About the MONET study

According to the MONET study published last year by the manufacturer of Darunavir, Tibotec, a Darunavir-boosted monotherapy (Darunavir-ritonavir 800-100 mg once daily) produced similar outcomes to the standard triple drug regimen after 48 weeks in therapy. The viral loads from both groups were statistically equivalent (viral load suppression less than 50 copies/mL) suggesting that the boosted monotherapy is as clinically effective as the triple drug regimen.  This finding is a promising beacon of light in the narrow tunnel currently traversed by AIDS therapy. Given enough research data, Darunavir Ethanolate CAS# 635728-49-3 monotherapy will simplify the current HAART in AIDS/HIV treatment, potentially resulting in an increase in patient adherence to therapy, reduced treatment costs and side effects.

LGM Pharma & AIDS Treatment Research

LGM Pharma currently supplies protease inhibitors and NARTIs to universities and pharmaceutical labs worldwide for research and development purposes. Just like its steadfast backing of cancer research, the company is actively engaged in AIDS treatment research. Just like the pharmaceutical companies that LGM Pharma currently supplies pharmaceutical products to, it understands the importance of putting quality above all else. It supplies only cGMP certified products to its suppliers while continuously monitoring every detail of its manufacture and movement down the supply chain which in turn gives its clients the confidence to go about their research and development of therapies for the AIDS pandemic.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service